SABMiller rejects AB InBev’s 3rd acquisition offer
BRUSSELS — Anheuser-Busch InBev’s plan to acquire fellow-beer maker SABMiller and form the “first truly global beer company” is once again stalled, as SABMiller’s board rejected the company’s latest acquisition offer on Wednesday.
AB InBev — which produces Budweiser and Corona, among other brands — offered SABMiller about 68 billion pounds ($108 billion), or about 42.15 pounds per share of the company on Wednesday in its third offer for acquisition. SAB Miller also rejected the previous two offers — one for 38 pounds per share on Sept. 22 and 40 pounds per share on Oct. 5.
“The Board of SABMiller has now met formally to consider the new proposal announced by AB InBev today,” SABMiller, which produces Coors and Miller brands of beer, among several others, said. “The Board, excluding the directors nominated by Altria Group Inc., has unanimously rejected the … proposal as it still very substantially undervalues SABMiller, its unique and unmatched footprint, and its standalone prospects.”
When it announced its offer, AB InBev was optimistic about its appeal to the SABMiller shareholders.
“We have the highest respect for SABMiller, its employees and its leadership, and believe that a combination of our two great companies would build the first truly global beer company,” AB InBev CEO Carlos Brito said. “By bringing together our rich heritage, brands and people we would provide more opportunities for consumers to taste and enjoy the world’s best beers. … Put simply, we believe we can achieve more together than each of us could separately, bringing more beers to more people and enhancing value for all of our stakeholders.”
General Mills issues recall of certain Cheerios, Honey Nut Cheerios
MINNEAPOLIS — General Mills on Tuedsay announced that it is recalling Cheerios and Honey Nut Cheerios products produced in its facility in Lodi, Calif. The products being recalled are labeled as being gluten free, but may in fact contain wheat as a result of an offloading issue when the company was transitioning five Cheerios cereals to be gluten free and wheat flour was introduced to the oat flour system.
“We want to reassure you that this was an isolated incident and we have implemented a solution to ensure that this will not happen again,” the company said. “The Cheerios and Honey Nut Cheerios produced at our other facilities are, and will continue to be, FDA compliant and gluten-free. We’ll also continue to test products and our oat flour supply extensively to ensure our products meet the gluten-free standard.”
The products being recalled are those Honey Nut Cheerios varieties with the following “better if used by” dates:
- and 25JUL2016LD.
Plain Cheerios being recalled have the following “better if used by” dates:
- and 17JUL2016 LD.
General Mills said that it’s safe for those who are gluten intolerant or have celiac disease to consume Cheerios products made at other facilities, as they were not affected. The company said that customers who can’t eat gluten and are affected by the recall should contact General Mills for a replacement of refund.
Bartell Drugs, Oberto team to fundraise for Seattle Children’s Hospital
SEATTLE — Bartell Drugs is teaming up with fellow Washington-based company Oberto Beef Jerky to help benefit Seattle Children’s Hospital. Throughout October, for every bag of Oberto jerky purchased at a Bartell Drugs location, a donation will be made to the hospital.
“Regardless of a family’s ability to pay, Seattle Children’s delivers world-class care and is recognized as one of the top children’s hospitals in the U.S.,” Bartell Drugs President and CEO Brian Unmacht said. “This collaborative fundraising effort focuses on supporting the important healthcare role that Seattle Children’s plays in our region.”
Bartell locations will feature promotional materials in-store and in advertisements for the rest of October, according to the company. Bartell and Oberto expect for their total contribution, to be presented to the hospital president by executives from both companies, to be around $25,000.